Kemal_YelekciProf. Dr. Kemal YELEKÇİ

Kadir Has Üniversitesi, Biyoinformatik ve Genetik Bölüm Başkanı


İletişim:

Tel:            0212 533 6532 / 1332
e-mail:      yelekci@khas.edu.tr


Eğitim:

ODTU Lisans: ODTÜ – Kimya Bölümü (1979)
cukurova Yüksek Lisans: Çukurova Üniversitesi – Organik Kimya Bölümü (1981)
ohio Doktora: Ohio Üniversitesi – Organik Kimya Bölümü (1987)
Danışman: Prof. W. Duane Huntsman, vefat etti

Akademik Deneyim:

northwestern Doktora Sonrası: Northwestern Üniversitesi – Medisinal Kimya Bölümü (1987-1988)
Danışman: Prof. Richard. B. Silverman
ege Yrd. Doç. Dr. ve Doç. Dr: Ege Üniversitesi – Kimya Bölümü (1988-1989)
marmara Doç. Dr. ve Prof. Dr.: Marmara Üniversitesi – Kimya Bölümü (1990 – 2001)
kadir has Prof. Dr. : Kadir Has Üniversitesi– Biyoinformatik ve Genetik Bölümü (2001-halen)

Ödüller:

*    2014 Akademi Ödülü (Kadir Has Üniversitesi tarafından araştırma ve eğitim başarısına göre verilmektedir)
*    Novartis Türkiye İlaç Tasarımı ve Geliştirilmesi ödülü (2008)

*    Kadir Has Üniversitesi Eğitim ve Araştırma Ödülü (5 kez)
*    NATO Research Grant 1995-1997 for the study of mechanism of monoamine oxidase (B) enzyme at Northwestern University.
*    NIH (National Institutes of Health) Grant for Post-doctoral study at Northwestern University.

*    DAAD Bursu (Goethe Enstitüsünde Almanca eğitimi için, Blaubeuren)
*    Fulbright Bursu (Ohio Üniversitesinde Doktora Eğitimi için)
*    ODTÜ yüksek şeref listesi öğrencisi
*    ODTÜ şeref listesi öğrencisi
*    Liseden üstün başarı ile mezun oldu


Verdiği Dersler

Lisans:

1.     General Chemistry
2.     Organic Chemistry
3.     Introduction to Spectroscpy

Lisansüstü:

1.     Introduction to Bioinformatics
2.     Organic Chemistry of Drug Design and Drug Action
3.     Special Topics in Medicinal Chemistry
4.     Introduction to Nuclear Magnetic Resonance (NMR)

Geçmiş Dersler:

Essential Cell Biology (Lisansüstü)
The Organic Chemistry of Drug Design and Drug Action (Lisansüstü)
Business Mathematics (Lisans)
History of Science (Lisans)


Üyelikler:

*    Türk Kimya Derneği
*    Amerikan Kimya Derneği (ACS)
*    ODTÜ İstanbul Mezunlar Derneği
*   epichembio grubu üyesi (http://epichembio.eu/epigenetic-chemical-probes/)


İdari görevler

*   Kadir Has Üniversitesi, Biyoinformatik ve Genetik Bölüm Başkanı (2008 – halen)
*   Kadir Has Üniversitesi Fen Bilimleri Enstitüsü müdürlüğü (2004-2006)
*   Kadir Has Üniversitesi Fen-Edebiyat Fakültesi Dekanı (2001-2006)
*   Kadir Has Üniversitesi Rektör Yardımcısı (2001-2003)
*   Marmara Üniversitesi Fen-Edebiyat Fakültesi Dekanı (1998-2001)
*   Marmara Üniversitesi Organik Kimya Anabilim Dalı Başkanı (1994-2000)
*   Marmara Üniversitesi Kimya Bölümü Başkanı (1988-2000)
*   Marmara Üniversitesi Kimya Bölümü Başkan Yardımcısı (1994-1998)
*   Marmara Üniversitesi Dekan Yardımcısı (1991-1992)
*   Ege Üniversitesi Kimya Bölüm Başkan Yardımcısı (1988-1989)


Araştırma konuları

Moleküler Dinamik ve Kuantum Mekanik Yöntemler Kullanılarak Rasyonel İlaç Tasarımı: Daha önce deneysel olarak sentezlenmis ve ilaç olarak kullanılan bileşiklere ait serbest bağlanma enerjilerinin (DG) ve İnhibisyon sabitlerinin (Ki) bilgisayar ortamında hesapsal yöntemler kullanılarak belirlenmesi. Buradan yola çıkarak daha önce hiç denenmemiş potansiyel ilaç adaylarına ait parametrelerin hasapsal kimya yoluyla bulunması. Bilgisayar destekli ilaç tasarımı.


Güncel Projeler:

tubitak TÜBİTAK-1001. SBAG 218S549  “Molecular modeling, synthesis, and potential anticancer activity of heteroaryl sulfanyl acetamide derivatives through apoptosis, angiogenesis and mPGES-1enzyme (Microsomal prostaglandin E2 synthase1) inhibitor.” Araştırmacı. Bütçe: 716,000 TL(2019-2022).
tubitak TÜBİTAK-1003. 2015S009  “Prostat Kanseri Tedavisi için Yeni Nesil Sentetik Ajanların Geliştirilmesi.” Araştırmacı. Bütçe: 2,817,996 TL (2016-2020)
cost COST Action. (CM1406) “Epigenetic Chemical Biology (EPICHEM)”. Araştırmacı. Bütçe: ~650,000 Avro (2015-2018)
7th framework FP7. Marie Curie Initial Training Networks (ITN). Call: FP7-PEOPLE-2013-ITN. Project ID: 608381. “Training in Neurodegeneration, Therapeutics Intervention & Neurorepair – TINTIN”. Araştırmacı. Bütçe: 3,817,235 Avro
(2013-2017)
itam İSTKA. “Özgün İlaç Keşfi, İlaç Geliştirilmesi ve İstanbul İlaç Sektörü’ne Bilgi ve Teknoloji Aktarma Amaçlı Bir Teknoloji Merkezi ve Üniversite-Sanayi İşbirliği Ağının Kurulması- İlaç Temel Araştırma Merkezi – İTAM”. 2012/BIL123. Araştırmacı. Bütçe: 1,788,000 TL (2012-2013)
cost COST Action CM1103. “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain”. Araştırmacı. Bütçe: 550,000 Avro (2011-2015)
tubitak TÜBİTAK-TBAG 211T100. “Nörodejeneratif Hastalıkların Önlenmesine Yönelik in silico Nöronal Nitrik Oksit Sentaz (nNOS) Seçimli İnhibitör Tasarımı”. Yürütücü. Bütçe: 19,350 TL (2012-2013)
tubitak TÜBİTAK 1007 (105G01) . “RNA Splicing Hatalarının Neden Olduğu Kalıtsal Hastalıklara İlaç Araştırma Gelşitirme Çalışmaları”. Araştırmacı. Bütçe: 1,577,827 TL (2006-2009)
6th framework FP6-MOBILITY. “Characterisation of Mitochondrial Proteins in Brain”.  Araştırmacı. Bütçe: 1,199,583 Avro (2006-2010)
tubitak TÜBİTAK-TBAG 108T232 “Design of new pyrazoline derivatives using molecular modelling; synthesis and determination of their inhibition kinetics by computational and experimental techniques”. Yürütücü. Bütçe: 298,000 TL (2008-2010)
tubitak TÜBİTAK-TBAG 1332 194T033 “Ekmek Mayası (Saccharomyces Cerevisiae) Yardımı ile L-3,4-Dihidroksifenil Alanin (L-Dopa) için Yeni Bir Sentez Yöntemi”. Yürütücü. (2000-2004)
tubitak TÜBİTAK-TBAG 520 “Melia Azedarach L. (Tesbih ağacı) Meyvelerinin Özütlerinden İzole Edilen Etkin Maddeler ve Pamuk Zararlıları Üzerine Etkileri”.  Araştırmacı. (1983-1986)

 


TÜBİTAK Panelleri ve Proje Danışmanlığı

2010′dan bu yana pek çok proje

Konferans Organizasyonu/İdaresi

*   10th International Amine Oxidase Workshop Ağustos 24, 2002 (İstanbul), Organizer and Chair.
*   13th International Amine Oxidase and Related Diseases Workshop, Beijing, Çin, Ekim 11 – 15, 2008, Komite.
*   Training School COST Action CM1103, Ekim 8, 2013, İstanbul. Organizer.
*   EpiChemBio (CM1406) and MuTaLig COST (CA15135), Porto/ Portekiz, Eylül, 2017. Program Komite.
*   Action CM1406: Epigenetic Chemical Biology ECI Workshop and Core Group Meeting, İstanbul, 2017. Organizer.
*   Training School Epigenetic Chemical Biology – Action CM1406 Computational Methods in Drug Design, 21.03.2018. İstanbul. Organizer.
*   The International Symposium on Health Informatics and Bioinformatics, (HIBIT),. Ekim 24, 2018. Antalya, TURKEY.  Komite.

Patent Başvurusu:

“Identification of potent and selective neuronal nitric oxide synthase inhibitors via fragment-based drug design approach”, (Türk Patent Enstitüsü başvuru tarihi: 23.12.2015-2015-TP101-614).


Books:

1.    Katarina Nikolic, Lazaros Mavridis, Teodora Djikic, Jelica Vucicevic, Danica Agbaba, Kemal Yelekci and John B. O. Mitchell, Computational approaches for multi-target drug design Drug Design for CNS Diseases: Screening Methodologies, Book Chapter, pp. 18-37, Ramsay, R. R., Di Giovanni, G., eds. (2017). Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases. Lausanne: Frontiers Media. doi: 10.3389/978-2-88945-123-4. (Book Chapter).
2.    Kemal Yelekçi, Turhan Altınata “Modern University Chemistry Problems“, (Turkish) Çağlayan Kitapevi, Beyoğlu, İstanbul, 1989. (ISBN 975-436-002-2).
3.    Kemal Yelekçi “Modern Nuclear Magnetic Resonance Spectroscopy and application”, (Turkish) Marmara Üniversitesi Teknik Eğtitim.Fak. Matbaası, İstanbul,1991, 362 pages.  (ISBN 975-400-064-6)

Yayınlar:

  1. Umut Salgin Goksen, Sevgi Sarigul, Patrick Bultinck, Wouter Herrebout, Ilknur Dogan, Kemal Yelekci, Gulberk Ucar, Nesrin Gokhan Kelekci, (2019), “Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity”, Chirality, 31, 21-23, https://doi.org/10.1002/chir.23027, (IF:1.833).
  2. Abdullahi Ibrahim Uba, Kemal Yelekçi (2019). Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors.” Journal of Biomolecular Structure and Dynamics, https://doi.org/10.1080/07391102.2018.1521747. (IF: 3.107
  3. Augustine S. Samorlu, Kemal Yelekçi, Abdullahi Ibrahim Uba (2019). “The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulation.” Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2018.1557559  (IF: 3.107).
  4. Abdullahi Ibrahim Uba, Kemal Yelekçi (2018). “ Identification of potential isoform- selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.” Journal of Biomolecular Structure and Dynamics, 36:12, 3231- 3245. http://doi.org/10.1080/07391102.2017.1384402 (IF: 3.107).
  5. Abdullahi Ibrahim Uba,  Kemal Yelekçi (2018). “Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.” Computational Biology and Chemistry, 77, 318-330. https://doi.org/10.1016/j.compbiolchem.2018.10.016, (IF: 1.412).
  6. Abdullahi Ibrahim Uba, Kemal Yelekçi (2018). “Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: structure-based virtual screening, molecular docking and dynamics simulation studies.” Computational Biology and Chemistry, 75: 131-142. https://doi.org/10.1016/j.compbiolchem.2018.05.004. (IF: 1.412).
  7. Göknil Coşkun, Teodora Djikic, Taha Hayal, Nezaket Türkel, Kemal Yelekçi, Fikrettin Şahin, Ş Küçükgüzel, “Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme InhibitorsMolecules 2018, 23, 1969; 2018 doi:10.3390/molecules23081969, (IF:3.09).
  8. Işıl Çoruh, Özge Çevik, Kemal Yelekçi, Teodora Djikic, Ş Güniz Küçükgüzel “Synthesis, anticancer activity, and molecular modeling of etodolac‐thioether derivatives as potent methionine aminopeptidase (type II) inhibitorsArchiv der Pharmazie, 3-4, 351, 2018. https://doi.org/10.1002/ardp.201700195 (IF:2.29).
  9. Teodora Djikic, Yasmina Martí, Francesca Spyrakis, Thorsten Lau, Paolo Benedetti, Gavin Davey, Patrick Schloss & Kemal Yelekci (2018). “Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities“, Journal of Biomolecular Structure and Dynamics, DOI: 10.1080/07391102.2018.1426044, (IF: 3.107).
  10. Abdullahi Ibrahim UBA, Kemal Yelekci (2017). Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors”, Turk J Biol 41, TÜBİTAK doi:10.3906/biy-1701-26. (IF: 0.651).
  11. S.T. Karadeniz, S.U. Akgul, Y. Ogret, H.S. Ciftci, A. Bayraktar, H. Bakkaloglu, Y. Caliskan, K. Yelekci, A. Turkmen, A.E. Aydin, F.S. Oguz, M. Carin, and F. Aydin, “Corrected Panel-Reactive Antibody Positivity Rates for Hypersensitized Patients in Turkish Population With Calculated Panel-Reactive Antibody Software”, http://dx.doi.org/10.1016/j.transproceed.2017.01.032, Transplantation Proceedings, 49, 445e447 (2017). (IF: 0.806).
  12. Karadeniz, Sedat Tanju; Akgul, Sabahat; Ciftci, Hayriye Senturk; Yelekci, Kemal; et al.“Epitope Based Hla Matching By Using Antibody Reactivity With High Resolution Allele Typing And HLA_match maker Algorithm Based Software” Transplant international, 30   Special Issue: SI   Supplement: 2   Pages: 302-302   Meeting Abstract, 2017. (IF: 3.196).
  13. Evranos-Aksoz, Begum; Ucar, Gulberk; Tas, Sadik Taskin; Yelekci, Kemal; et al.“New Human Monoamine Oxidase an Inhibitors with Potential Anti-Depressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity”, Combinatorial chemistry & high throughput screening, 20   Issue: 6   Pages: 461-473, 2017. (IF: 1.205).
  14. Evranos-Aksoz, Begum; Ucar, Gulberk; Yelekci, Kemal, “Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline AnaloguesCombinatorial chemistry & high throughput screening, 20, Issue: 6   Pages: 510-521, 2017. (IF: 1.205).
  15. Katarina Nikolic, Lazaros Mavridis, Teodora Djikic, Jelica Vucicevic, Danica Agbaba, KemalYelekci andJohnB.O.Mitchell. “Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies”  http://dx.doi.org/10.3389/fnins.2016.00265. Front. Neurosci., 10 June 2016 (IF: 3.877).
  16. Evranos-Aksöz B, Baysal İ, Yabanoğlu-Çiftçi S, Djikic T, Yelekçi K, Uçar G, Ertan R. “Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.“. Arch Pharm (Weinheim). 2015 Oct;348(10):743-56. doi: 10.1002/ardp.201500212. Epub 2015 Aug 21. (2015) (IF: 2.288).
  17. F. Pinar Turkmenoglu, İpek Baysal, Samiye Ciftci-Yabanoglu, Kemal Yelekci,  Hamdi Temel, Salih Paşa, Nurten Ezer, İhsan Çalış and Gulberk Ucar., “Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol.” Molecules Journal, 2015 Apr 23;20(5):7454-73. doi: 10.3390/molecules20057454. (2015) (IF: 3.098)
  18. Kemal Yelekci, Bahanur Örtmen., “De Novo Design of Potent and Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors by a Fragment-Based Approach“, Journal of Pharmaceutical Chemistry, ISSN: 2349-5731 (2015)
  19. Malcomson T, Yelekci K, Mar Borrello MT, Ganesan A, Semina E, De Kimpe R, Mangelinckx S, Ramsay RR.,  “cis-Cyclopropylamines as mechanism-based inhibitors of Monoamine Oxidases”,  FEBS Journal, DOI: 10.1111/febs.13260, (2015) (IF: 4.53).
  20. Evranos-Aksöz B, Yabanoğlu-Çiftçi S, Uçar G, Yelekçi K, Ertan R. “Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory activities and docking studies.” Bioorg Med Chem Lett. 2014. 1;24(15):3278-84. (DOI: 10.1016/j.bmcl.2014.06.015) (2014) (IF: 2.442).
  21. Kemal Yelekçi, Bora Büyüktürk, Nurdan Kayrak, “In silico identification of novel and selective monoamine oxidase B inhibitors”. J Neural Transm 2013. 120:853–858, (DOI 10.1007/s00702-012-0954-0) (2013) (IF: 2.779).
  22. Umut Salgın-Gökşen, Nesrin Gökhan-Kelekçi, Samiye Yabanoğlu-Çiftçi, Kemal Yelekçi, Gülberk Uçar, “Synthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivatives”. J Neural Transm . 2013. 120:883–891, (DOI 10.1007/s00702-013-0968-2) (2013) (IF: 2.779).
  23. Umut Salgın-Gökşen, Samiye Yabanoğlu-Çiftçi, Ayşe Ercan, Kemal Yelekçi, Gülberk Uçar, Nesrin Gökhan-Kelekçi, “Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives”. J Neural Transm, 2013. 120:863–873, (DOI 10.1007/s00702-013-0980-6). (2013) (IF: 2.779).
  24. Safiye Sağ Erdem, Seyhan Türkkan, Kemal Yelekçi, Nesrin Gökhan-Kelekçi, “Insights into the binding mode of new N-substituted pyrazoline derivatives to MAO-A: docking and quantum chemical calculations”. J Neural Transm, 2013. 120:859–862,   (DOI 10.1007/s00702-012-0950-4) (2013) (IF: 2.779).
  25. Gamze Bora Tatar, Tenzile Deniz Tokluman, Kemal Yelekçi, Hayat Yurter,“Power of inhibition activity screening and 3D molecular modeling approaches in HDAC 8 inhibitor design”. Turk J Chem, 35 . 2011. 861 – 870. (doi:10.3906/kim-1107-34) (2011) (IF: 1.377).
  26. Ebru Demet Akdoğan, Burak Erman, Kemal Yelekçi. “In silico design of novel and highly selective lysine-specific histone demethylase inhibitors”. Turk J Chem 35. 2011. 523-542, (doi:10.3906/kim-1102-985) (2011) (IF: 1.377).
  27. Nesrin Gökhan-Kelekçi, Ö. Özgün Şimşek, Ayşe Ercan, Kemal Yelekçi, Z. Sibel Şahin Şamil Işık, Gülberk Uçar, A. Altan Bilgin. “Synthesis and molecular modeling of some novel hexahydroindazole derivatives as “potent monoamine oxidase inhibitors”. Bioorganic & Medicinal Chemistry. 2009, 17(4), 5219-5228. (2009) (IF: 2.881).
  28. Gamze Bora-Tatar, Didem Dayangaç-Erden, Ayhan S. Demir, Sevim Dalkar, Kemal Yelekçi, Hayat Erdem-Yurter, “Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies”. Bioorganic & Medicinal Chemistry. 2009. 17(18), 6761-6772. (2009) (IF: 2.881).
  29. Didem Dayangaç-Erden, Gamze Bora, Peruze Ayhan, Çetin Kocaefe, Sevim Dalkara, Kemal Yelekçi, Ayhan S. Demir, Hayat Erdem-Yurter, “Histone Deacetylase Inhibition Activity and Molecular Docking of (E )-Resveratrol: its Therapeutic Potential in Spinal Muscular Atrophy”. Chemical Biology & Drug Design. 2009, 37(3), 355-364. (2009).

  1. Nesrin Gökhan-Kelekçi, Semra Koyunoğlu, Samiye Yabanoğlu, Kemal Yelekçi, Özen Özgen, Gulberk Uçar, Kevser Erol, Engin Kendi, Akgul Yeşilada,”New Pyrazoline Bearing 4(3H)-quinazolinone Inhibitors of Monoamine Oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity“. Bioorganic & MedicinalChemistry. 2009. 17(2), 675-689. (2009)
  2. Kemal Yelekçi, Özlem Karahan, Mustafa Toprakçı “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties (ΔG and Ki)”. Journal of Neural Transmission, 2007.114: 725-732. (2007)
  3. kapak

    Safiye Sağ Erdem, Ö zlem Karahan, İbrahim Yıldız and Kemal Yelekçi .“A computational study on the amine-oxidation mechanism of monoamine oxidase: Insight into the polar nucleophilic mechanism”. Organic & Biomolecular Chemistry, 2006, 4, 646-658. (2006). (Bu makale “The Royal Soceity of Chemistry” kapsamında uluslararası yayınlanan  dergiye kapak olmuştur.)

  4. Mustafa Toprakçı, Kemal Yelekçi. “Docking studies on Monoamine Oxidase-B inhibitors: estimation of inhibition constants (Ki) of   a series of experimentally tested compounds”. Bioorganic & Medicinal Chemistry Letters, 15. 2005. 4438-4446. (2005)
  5. K. Yelekçi; R.B. Silverman “Effect of the Locus of the Oxygen Atom in Amino Ethers on The Inactivation of Monoamine Oxidase B”. J. Enzyme Inhibition. 1998, 13, 31-39. (1998)
  6. V.J. Drose; J.C.G. Woo; W.P.Hawe; B.M. Hoffman; R:B: Silverman; K. Yelekçi “Observation of a Flavin Semiquinone in the Resting Staate of Monoamine Oxidase by Electron Paramagnetic resonance and Electron Nucleer Double Resonance”. Biochemistry 1996, 35, 11085-11091. (1996)

Uluslararası Kongreler:

  1. Kemal Yelekçi, Abdullahi I. Uba, “Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors””, VII Serbian Congress of Pharmacy, October 10‐14, 2018, Belgrade, Serbia.
  2. Kemal Yelekçi, Abdullahi I. UBA, “In Silico Modeling of Human Dopamine Transporter”, The International Symposium on Health Informatics and Bioinformatics, (HIBIT), October 25, 2018. Antalya, TURKEY.
  3. Kemal Yelekçi, Abdullahi I. Uba, “In silico modeling of histon deacetyase enzyme and design of novel inhibitors Computational Chemistry: Application of Molecular Dynamics Simulation and Docking Approaches in Drug Design”. Turkey,            Epigenetic Chemical Biology – Action CM1406 Computational Methods in Drug Design, 21.03.2018.
  4. Kemal Yelekci, Abdullah İbrahim Uba, The search for potential selective inhibitors of human histone deacetylase 6 via pharmacophore-based virtual screening. European Cooperation in Science and Technology (COST) Action CM1406: Epigenetic Chemical Biology ECI Workshop and Core Group Meeting, Institut Pasteur, 15th February, 2018, Paris, FRANCE.
  5. Abdullahi İbrahim Uba, Kemal Yelekci. Molecular modelling studies on the recently-solved crystal structure of human histone deacetylase 6 catalytic domain 2 complexed with known inhibitors and the design of potential inhibitors for cancer therapy. 5th Multithematic Biomedical Congress (IMBMC), European University, Cyprus 2nd-4th November, 2017, Nicosia, CYPRUS (GREEK CYPRUS)
  6. Kemal Yelekçi, “In silico identification of Isoform-Selective HDAC Inhibitors”, EpiChemBio (CM1406) and MuTaLig COST (CA15135), Porto/ Portugal, September, 2017.
  7. Kemal Yelekci, Teodora Djikic, “In silico Modeling of Dopamine Transporter and Design of Novel Neuroprotective Agents”, 252nd ACS National Meeting in Philadelphia, PA, USA, August 21, 2016.
  8. Yelekçi, K. ve Djikic, T. “In Silico Modeling of Human Dopamine Transporter and Design of Novel Inhibitors.” 51st International Conference on Medicinal Chemistry, 01-03.07.2015, Avignon, France.
  9. Yelekçi, K. 2015. “Molecular Docking Studies on Hydroxamic Acid Derivatives as Potential Anticancer Agents via Histone.” COST-EPIGEN Meeting, October 28, 2015, Budapest.
  10. Yelekçi, K. ve Connaly, J. “Homology Modeling of the Human Dopamine Transporter (Hdat): The Elucidation of the Binding Site.” Conference Proceedings EU COST Action CM1103, 8-10 October, 2014, Bordeaux, France.
  11. Rona R. Ramsay, Thomas Malcomson, A. Ganesan, Sven Mangelinckx, Kemal Yelekci, “Cylopropylamine drugs for LSD1 and MAO: Inactivation of MAO”, 18th International Symposium on Flavins and Flavoproteins, July 27- August 1, 2014, THAILAND.
  12. Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan, “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
  13. Ucar, GEvranos-Aksoz, BYabanoglu-Ciftci, S; Yelekci, Kemal, “Design and synthesis of novel 2-pyrazoline analogues and their hMAO inhibitory activities, 40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) – The Biochemical Basis of Life, : Berlin, GERMANY, JUL 04-09, 2015.
  14. Evranos-Aksoz, B.; Yabanoglu-Ciftci, S.; Ucar, G; Kemal Yelekçi. “Synthesis and screening of hMAO inhibitory activities of some new 2-pyrazoline and hydrazone derivatives”, FEBS EMBO 2014 Conference Location: Paris, FRANCE Date: AUG 30-SEP 04, 2014.
  15. Begüm Evranos-Aksoz, Samiye Yabanoglu-Ciftci, Gülberk Ucar, Kemal Yelekçi, Rahmiye Ertan ,. “Synthesis and screening of hmao inhibitory activities of some new 2-pyrazoline and hydrazone derivatives” (FEBS_EMBO-3960), FEBS EMBO 2014 Conference, 30 August to 4 September 2014, Paris.
  16. Kemal Yelekçi, “Novel Synthesis and Molecular Modeling of 3-Substituted Aryl-5-(2-Furanyl)-4,5-Dihydro-(1H)-Pyrazol.” Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases: Dissecting and Modulating Complex Function in the Monoaminergic Systems of the Brain, 22-24.04.2014, Bratislava/Slovakya.
  17. Kemal Yelekçi, “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and Its Practical Application.” Program of Training School COST Action CM1103, 09-13.09.2013, Istanbul.
  18. Kemal Yelekçi, “In Silico Design of Novel and Selective Neuronal Nitric Oxide Synthase (Nnos) Inhibitors.” CM1103 Action Conference in Malta: Interdisciplinary Chemical Approaches, 22-25.11.2013, Valletta, Malta.
  19. Kemal YELEKÇİ, A. Bora BÜYÜKTÜRK, Nurdan KAYRAK, Serkan Altuntaş, “In silico design of novel and highly selective neuronal nitric oxide synthase (nNOS) inhibitors”, 2013 RICT- Drug Discovery and Selection, When Chemical Biology meets Drug Design, Nice, France, July 3-5, 2013.
  20. Kemal Yelekci, (Keynote Speaker). “Molecular Docking for Predicting Optimal Protein-Ligand Interaction: Principles and its practical application” Summer School: From Computational Enzymology towards Molecular Docking Venue: Main Lecture roomat The National Institute of Chemistry, Ljubljana/Slovenia. May 31, 2013.
  21. Kemal Yelekçi, (invited speaker), “Design of selective monoamine oxidase B inhibitors using saffinamide as a scaffold”, CM1103 Action WG Meeting 24-26 November 2012 Madrid, Spain.
  22. Kemal Yelekci, “In silico design of novel and highly selective monoamine oxidase B inhibitors”, 16-18 july: 15th Amine Oxidase Congress 2012, Toulouse, France.
  23. Kemal Yelekçi, “De novo design of lysine specific histon demethylase (LSD1) inhibitors”, Silverman Symposium (tribute to Prof Richard B. Silverman’s 65th birth day), May 13, 2011, Northwestern University, Evanston, Chicago.
  24. Kemal Yelekçi, “Analysis of monoamine oxidase A and B active sites: evaluation of de novo designed pyrazoline derivatives and pharmacophore generation” The 14th Biennial International Amine Oxidase Workshop, University of Alberta, Edmonton, CANADA, July 18th-21at, 2010.
  25. Kemal Yelekci, “Methods and solutions for lead discovery and optimization, structure and fragment-based design, transmembrane protein analysis, and enzyme modeling”, Workshop European DS Pharmacophore Meeting, 1-3 July 2009, Romainville, Paris, FRANCE.
  26. Kemal Yelekçi, Nesrin Gökhan-Kelekci, Samiye Yabanoğlu, Gülberk Uçar, “Design and Biological Evaluation of New Pyrazoline Bearing 4(3H)-Quinazolinone Inhibitors of Monoamine Oxidase A and B: Binding Mode Studies Performed Through Docking Procedures”, 13th International Amine Oxidase and Related Diseases Workshop ,Century HuatianHotel, Beijing, China, October 11 – 15, 2008.
  27. Kemal Yelekci, “Thermal rearrangement of 2-acetoxy-2,6,6 trimethylbicyclo [3.1.0] hexane: Theoretical elucidation of the mechanism”234th ACS National Meeting, Boston, MA, (USA), August 19-23, 2007.
  28. Kemal Yelekçi, Mustafa Toprakçı, “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties”, 232nd ACS National Meeting, San Francisco, CA, USA, September 10-14, 2006,
  29. Kemal Yelekçi, Özlem Karahan, Mustafa Toprakçı “Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites”, “12th International Amine Oxidase Workshop “, University of Erasmus, August 30, 2006, Rotterdam, Nederland.
  30. M. Toprakçı, K. Yelekçi, “Binding affinity prediction of oxygen containing heptylamines as monoamine oxidase inactivators by molecular dynamics calculations.”11th Amine Oxidase Workshop, University of St. Andrews, July 25, 2004, Scotland.
  31. M. Toprakçı, K. Yelekçi, “Molecular Mechanics Analysıs of Binding Affinties of two Putative Ligands for Monoamine Oxidase-B Enzyme.”, 10th Amine Oxidase Workshop, University of Kadir Has, August 25, 2002, Istanbul, TURKEY.
  32. Kemal Yelekçi, R.B. Silverman, S. S. Erdem, “Inductive Effect of a Heteroatom Containing Heptylamine Analogues on MAO B.” 9th International Amine Oxidase Workshop, The Millennium Meeting, Barcelona, July 9th-12th, 2000.
  33. Kemal Yelekçi, NATO Advanced Study Institute on “Molecular Aspects of Monooxygenases and Bioactivation of Toxic Compounds” Oxidation Mechanism of Monoamine Oxidase.” August 27-September 7,1989 Çeşme, İZMİR-TURKEY
  34. Kemal Yelekçi, American Chemical Society 191st National Meeting, New York, NY April 13-18, 1986.

 


Yönetilen Tezler:

  1. Safanah Albayati.  Master’s Thesis. “Selective and Potent Inhibitors Design for Methionine Aminopeptidase II (MetAPs II) using Pharmacophore Modeling” (2019)
  2. Şafak Naz Şentürk. Master’s Thesis. “Peptidomimetic drug candidates for methionine amino peptidase II enzyme for prevention of cancer”. (2019)
  3. Augustine S. Samorlu. Master’s Thesis. “In silico screening of potent HIV-1 integrase inhibitors for the treatment of human immunodeficiency virus (HIV)”. (2018)
  4. Abdullahi Inrahim Uba. PhD Thesis. “Targeting cancer epigenetic modifiers: The design of isoform-selective histone deacetylase inhibitors” (2018)
  5. Teodora Djikic. PhD Thesis. “In silico modeling of dopamine transporter and design of novel neuroprotective drugs for Parkinson’s disease” (2017)
  6. Sedat Tanju Karadeniz. Master’s Thesis. “Corrected PRA positivity rates for hypersensitized patients in Turkish population with calculated PRA-cPRA software”. (2017)
  7. Jackson Weako. Master’s Thesis. “In silico screening of tangible-potential inhibitor of methionine aminopeptidase 2 for the treatment of cancer”. (2017)
  8. Sinan Fındık. Master’s Thesis. “Exploring the action mechanism of amphipathic alpha -Helical Antimicrobial Peptides, Ll-23 And Its Single-Nucleotide Variants Via Computational Methods”. (2016)
  9. Fatma M.Ab. Alnemsi. Master’s Thesis. “Docking study of resveratrol like molecules on histone deacetylase 8″. (2016)
  10. Dilara Karaman. Master’s Thesis. “In silico design and modeling of coumarin derivatives as selective monoamine oxidase inhibitors”. (2014)
  11. Bahanur Örtmen. Yüksek Lisans Tezi. “In silico screening of neuronal nitric oxide synthase enzyme inhibitors”. (2014)
  12. Dilara Karaman. Yüksek Lisans Tezi. “In silico design and modeling of coumarin derivatives as selective monoamine oxidase A inhibitors”. (2014).
  13. Tuğba Mehmetoğu. Yüksek Lisans Tezi. “In silico design of novel and highly selective cyclooxygenase-2 inhibitors”. (2014)
  14. Talha Karabıyık. Yüksek Lisans Tezi. “In silico identification of physiological substrates and inhibitors of serum paraoxonase I enzyme”. (2014)
  15. Nurdan Kayrak. Yüksek Lisans tezi. “nNOS selective inhibitor identification using de novo design methods”. (2013)
  16. Bora Büyüktürk. Yüksek Lisans Tezi. “Exploration of binding sites of nNOS isozymes to design selective neuronal nitric oxide synthase inhibitors”. (2013)
  17. Serkan Altuntaş. Yüksek Lisans Tezi. “In silico screening of monoamine oxidase A and B inhibitors using indane ring as a scaffolds”. (2013)
  18. Çağla Mıdık. Yüksek Lisans Tezi. “Monoamin oksidaz A ve B (MAO-A, MAO-B) enzimlerine ihnibitör olarak 1-tiocarbomoyil, 3-fenil, 5-furfuril, 2-pirazolin iskeleti kullanılarak daha aktif türevlerinin moleküler modelleme yöntemiyle tasarlanması”. (2012)
  19. Filiz Varnalı. Yüksek Lisans Tezi. “Monoamin oksidaz A ve B (MAO-A, MAO-B) enzimlerine inhibitör olarak 1-benzoksazilidinone-3,5-difenil-2-pirazolin iskeleti kullanılarak türevlerinin moleküler modelleme yöntemiyle tasarlanması”. (2012)
  20. Erçin Dinçer. Yüksek Lisans Tezi. “Tüberküloz (Mycobacterium Tuberculosis) bakterisinin LAM 7 suşunun rpoB geninin kodladığı rifambisin hedefini oluşturan proteinin homology modellenmesi ve mutasyona uğramış LAM 7 suşlarında oluşan dirence karşı yeni ilaç tasarımı”. (2012)
  21. Seyhan Türkkan. Yüksek Lisans Tezi. “Monoamin A ve Monoamin B enzimlerinine İnhibitör Tasarımı”. (2012)
  22. Özlem Karahan. Yüksek Lisans Tezi. “Monoamin oksidaz (MAO) enziminin aminleri oksitleme mekanizmasının hesapsal yöntemlerle incelenmesi”. (2004)
  23. İbrahim Yıldız. Yüksek Lisans Tezi. “Mono amin oksidaz (MAO) enziminin ekleme eliminasyon mekanizmasının hesapsal yöntemlerle incelenmesi”. (2003)
  24. Gül Altınbaş. Yüksek Lisans Tezi. “Benzen ve toluenin değişik substratlarla Friedel Crafts açilasyon reaksiyonlarının incelenmesi”. (2001)
  25. Dilber Damar. Yüksek Lisans Tezi. “Etil 2-nitro-3-hidroksi-3-(3,4-dimetoksifenil) propanoat’ın sentezi”. (2001)
  26. Sevim Karataş. Doktora Tezi. “Etil alfa-halo-3,4-disübstitüesinnamat ile alfa-açilamino-3,4-disübstitüe sinnamik asit bileşiklerinin sentezi ve Pd/C ile indirgenme ürünleri”. (2001)
  27. Memet Vezir Kahraman. Doktora Tezi. “Biyolojik aktif amino eter sentezleri”. (2001)
  28. Memet Vezir Kahraman. Yüksek Lisans Tezi. “α-(2-aminometil)-N-fenilnitron sentezi”. (1995)